secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001628280-23-015454
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Q1 net loss widens to $34.8M; cash runway into 2025
-------------------------------------------------------------------

- Net loss of $34.8M ($0.71 per share) vs. $31.6M ($0.65) in Q1 2022; revenue dropped to $3.8M from $7.7M.
- R&D expense rose to $29.0M (Q1 2022: $26.2M) driven by clinical trial costs for CFT7455, CFT8634, CFT1946.
- Cash, equivalents and marketable securities were $305.0M as of March 31, 2023, expected to fund operations into 2025.
- Phase 1 dose-escalation data for CFT7455 (monotherapy in multiple myeloma) and CFT8634 (synovial sarcoma) expected in H2 2023.
- IND submission for CFT8919 (NSCLC) targeted for H1 2023; first patient dosed in CFT1946 Phase 1/2 trial in January.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023015454/0001628280-23-015454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023015454/cccc-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer